GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRPα, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric SIRPα.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric SIRPα is operably linked to an endogenous regulatory element at the endogenous SIRPα gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric SIRPα comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 4.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric SIRPα comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 8 claim 1 , 25 claim 1 , 26 claim 1 , 27 claim 1 , or 28.5. The animal of claim 1 , wherein the human or chimeric SIRPα comprises a sequence that is at least 90% identical to amino acids 31-138 of SEQ ID NO: 4.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous SIRPα.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric SIRPα.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous SIRPα with a sequence encoding a corresponding region of human SIRPα at an endogenous SIRPα gene locus.13. (canceled)14. (canceled)15. The animal of claim 12 , wherein the replaced locus is the extracellular region of SIRPα.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric SIRPα having an extracellular region claim 12 , wherein the extracellular region comprises a sequence that is at ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL15

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a cDNA sequence encoding an exogenous IL15 polypeptide , wherein the exogenous IL15 polypeptide comprises a sequence that is a least 80% identical to SEQ ID NO: 4 , wherein the animal has one or more cells expressing the exogenous IL15 polypeptide.2. The animal of claim 1 , wherein the sequence encoding a human or chimeric IL15 comprises a sequence encoding an amino acid sequence that is at least 90% identical to SEQ ID NO: 4.3. The animal of claim 1 , wherein the cDNA sequence comprises a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) sequence and/or a polyA (polyadenylation) signal sequence.4. The animal of claim 1 , wherein the cDNA sequence is operably linked to an endogenous regulatory element at the endogenous IL15 gene locus in the at least one chromosome.5. The animal of claim 1 , wherein the cDNA sequence is operably linked to an endogenous 5′-UTR.6. The animal of claim 1 , wherein the animal is a mammal.7. The animal of claim 1 , wherein the animal in its genome comprises a sequence that is at least 80% identical to SEQ ID NO: 6.8. The animal of claim 1 , wherein the animal does not express endogenous IL15.9. (canceled)10. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises an insertion of a sequence encoding an exogenous IL15 polypeptide at a locus within exon 3 of an endogenous IL15 gene locus.11. The animal of claim 10 , wherein the sequence encoding the exogenous IL15 polypeptide is operably linked to the 5′-UTR at the endogenous IL15 locus.12. (canceled)13. The animal of claim 10 , wherein the animal does not express endogenous IL15.14. The animal of claim 10 , wherein the sequence encoding the exogenous IL15 ...

Herbicide-resistance gene and application thereof in plant breeding

Provided are a mutant HPPD polypeptide having high resistance to a herbicide and an encoding gene thereof, and an application thereof in an improved plant. The amino acid at position 282 of the mutant HPPD polypeptide is mutated from arginine to serine at a wild-type HPPD polypeptide. In addition, the mutant HPPD polypeptide further comprises an amino acid at position 349 that is mutated from glutamic acid to lysine, and/or an amino acid at position 156 that is mutated from alanine to valine. The mutated HPPD polypeptide can be used for cultivating plants having resistance to a herbicide having HPPD inhibition.

Power adapter

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complex, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD27

The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice) that express a human or chimeric (e.g., humanized) CD27. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice), and methods of using the genetically modified non-human animals (e.g., genetically modified mice) described herein.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC LAG3

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a chimeric LAG3 , wherein the sequence comprises humanized LAG-3 exons 2-7 , and an endogenous LAG-3 exon 8.2. The animal of claim 1 , wherein the sequence encoding the chimeric LAG3 is operably linked to an endogenous regulatory element at the endogenous LAG3 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the chimeric LAG3 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 44.4. The animal of claim 1 , wherein the chimeric LAG3 comprises an amino acid sequence that is identical to SEQ ID NO: 44.5. The animal of claim 1 , wherein the chimeric LAG3 consists of an amino acid sequence that is identical to SEQ ID NO: 44.6. The animal of claim 1 , wherein the chimeric LAG3 comprises a sequence that is at least 80% identical to amino acids 25-465 of SEQ ID NO: 4.7. The animal of claim 1 , wherein the animal is a rodent.8. The animal of claim 1 , wherein the animal is a mouse.9. The animal of claim 1 , wherein the animal does not express endogenous LAG3.10. The animal of claim 1 , wherein the animal has one or more cells expressing the chimeric LAG3.1112.-. (canceled)13. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a nucleotide sequence comprising a contiguous sequence starting at exon 2 and ending at exon 7 of endogenous LAG3 with a nucleotide sequence comprising a contiguous sequence starting at exon 2 and ending at exon 7 of human LAG3 at an endogenous LAG3 gene locus.14. The animal of claim 13 , wherein the contiguous sequence of endogenous LAG3 starts from within exon 2 and ends within exon 7 claim 13 , wherein the contiguous sequence of human LAG3 starts from ...

Genetically modified non-human animal with human or chimeric SIRPa

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRPα, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD137

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof. 157.-. (canceled)58. A genetically-modified , non-human mammal whose genome comprises at least one chromosome comprising at an endogenous CD137 gene locus a replacement of a nucleic acid sequence encoding a portion of the extracellular region of an endogenous CD137 protein with a nucleic acid sequence encoding a portion of the extracellular region of a human CD137 protein , wherein the non-human mammal detectably expresses a chimeric CD137 protein comprising a humanized CD137 extracellular region and an endogenous CD137 cytoplasmic region on the surface of activated T cells , wherein the sequence encoding the chimeric CD137 protein is operably linked to an endogenous regulatory element at the endogenous CD137 gene locus in the at least one chromosome , wherein the expressed chimeric CD137 protein can be recognized by an anti-human CD137 antibody , and wherein the anti-human CD137 antibody can increase immune response in the mammal.59. The mammal of claim 58 , wherein the chimeric CD137 protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 18.60. The mammal of claim 58 , wherein the chimeric CD137 protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 24.61. The mammal of claim 58 , wherein the chimeric CD137 protein comprises an amino acid sequence that is at least 80% identical to amino acids 1-184 of SEQ ID NO: 18.62. The mammal of claim 58 , wherein the mammal is a rodent.63. The mammal of claim 58 , wherein the mammal is a mouse.64. The mammal of claim 58 , wherein the mammal does not express endogenous CD137.65. The mammal of claim 60 , wherein the chimeric CD137 protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 24.66. The mammal of claim 60 , wherein the chimeric CD137 protein comprises an amino acid ...

Genetically Modified Non-Human Animal With Human Or Chimeric TIGIT

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Speaker

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD28

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric CD28.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric CD28 is operably linked to an endogenous regulatory element at the endogenous CD28 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD28 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 29.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD28 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 33.5. The animal of claim 1 , wherein the human or chimeric CD28 comprises a sequence that is at least 90% identical to amino acids 28-150 of SEQ ID NO: 29.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous CD28.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric CD28.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous CD28 with a sequence encoding a corresponding region of human CD28 at an endogenous CD28 gene locus.1314.-. (canceled)15. The animal of claim 12 , wherein the replaced locus is the extracellular region of CD28.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric CD28 having an extracellular region claim 12 , a transmembrane region claim 12 , and a cytoplasmic region claim 12 , wherein the extracellular region comprises a sequence that is at least ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL6R and/or IL6, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD73

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD73, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMAN OR CHIMERIC THPO

The present disclosure relates to genetically modified non-human animals expressing human or chimeric (e.g., humanized) Thrombopoietin (THPO), and methods of use thereof.

Genetically modified non-human animal with human or chimeric GITR

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) glucocorticoid-induced TNFR-related protein (GITR), and methods of use thereof.

Genetically modified non-human animal with human or chimeric genes

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

Immunodeficient non-human animal

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof.

Fast startup control circuit for switch mode power supply

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GITR

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) glucocorticoid-induced TNFR-related protein (GITR), and methods of use thereof.

Speaker

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33

Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL33, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric IL33.2. The animal of claim wherein the sequence encoding the human or chimeric IL33 is operably linked to an endogenous regulatory element at the endogenous IL33 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric IL33 is operably linked to an endogenous 5′ untranslated region (5′UTR).4. The animal of any one of - claim 1 , wherein the sequence encoding a human or chimeric IL33 comprises a sequence encoding an amino acid sequence that is at least 70% claim 1 , 75% claim 1 , 80% claim 1 , 85% claim 1 , 90% claim 1 , 95% claim 1 , 99% claim 1 , or 100% identical to human IL33 (SEQ ID NO: 8 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 10 claim 1 , SEQ ID NO: 11 claim 1 , or SEQ ID NO: 12).5. The animal of claim 4 , wherein the sequence encoding a human or chimeric IL33 comprises a sequence encoding an amino acid sequence that is at least 70% claim 4 , 75% claim 4 , 80% claim 4 , 85% claim 4 , 90% claim 4 , 95% claim 4 , 99% claim 4 , or 100% identical to SEQ ID NO: 8.6. The animal of claim 4 , wherein the sequence encoding a human or chimeric IL33 comprises a sequence encoding an amino acid sequence that is at least 70% claim 4 , 75% claim 4 , 80% claim 4 , 85% claim 4 , 90% claim 4 , 95% claim 4 , 99% claim 4 , or 100% identical to SEQ ID NO: 9.7. The animal of claim 4 , herein: the sequence encoding a human or chimeric IL33 comprises a sequence encoding an amino acid sequence that is at least 70% claim 4 , 75% claim 4 , 80% claim 4 , 85% claim 4 , 90% claim 4 , 95% claim 4 , 99% claim 4 , or 100% identical to SEQ ID NO: 10.8. The animal of claim 4 , wherein the sequence encoding a human or chimeric IL33 comprises a sequence ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD137

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric CD137.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric CD137 is operably linked to an endogenous regulatory element at the endogenous CD137 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD137 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 18.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD137 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 24.5. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD137 comprises a sequence encoding an amino acid sequence that is at least 80% identical to amino acids 1-184 of SEQ ID NO: 18.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous CD137.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric CD137.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous CD137 with a sequence encoding a corresponding region of human CD137 at an endogenous CD137 gene locus.13. (canceled)14. (canceled)15. The animal of claim 12 , wherein the replaced locus is the extracellular region of CD137.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric CD137 having an extracellular region claim 12 , a transmembrane region claim 12 , and a cytoplasmic region claim ...

BASE STATION ANTENNA AND BASE STATION

A base station antenna and a base station including the base station antenna are provided. A base station antenna includes a transceiver array configured to output M signals, wherein M is an integer greater than 1; an antenna array including N antenna units, wherein N is an integer greater than M; a first-level signal allocating network configured to allocate first power to the M signals, and output P signals, wherein P is an integer greater than M; a signal synthesizing network including multiple signal synthesizers, wherein each of the multiple signal synthesizers utilizes two signals of the P signals to synthesize two output signals; and a second-level signal allocating network configured to allocate second power to signals output by the multiple signal synthesizers, and output N signals to the N antenna units. 1. A base station antenna , comprising:a transceiver array configured to output M signals, wherein M is an integer greater than one;an antenna array including N antenna units, wherein N is an integer greater than M;a first-level signal allocating network configured to allocate first power to the M signals, and output P signals, wherein P is an integer greater than M;a signal synthesizing network including multiple signal synthesizers, wherein each of the multiple signal synthesizers utilizes two signals of the P signals to synthesize two output signals; anda second-level signal allocating network configured to allocate second power to signals output by the multiple signal synthesizers, and output N signals to the N antenna units.2. The base station antenna of claim 1 , wherein each of the multiple signal synthesizers comprises a microstrip line on a dielectric substrate.3. The base station antenna of claim 1 , wherein for any two groups of antenna units in the antenna array claim 1 , a sum of phases of each antenna unit in a first group of antenna units is equal to a sum of phases of each antenna unit in a second group of antenna units claim 1 , andwherein ...

Genetically modified non-human animal with human or chimeric OX40

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) TNFR2, and methods of use thereof.

IMMUNODEFICIENT NON-HUMAN ANIMAL

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof ...

Genetically modified non-human animal with human or chimeric CD137

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.

Genetically modified non-human animal with human or chimeric TIGIT

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TIM-3

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric T-cell immunoglobulin and mucin-domain containing-3 (TIM-3).2. The animal of claim 1 , wherein the sequence encoding the human or chimeric TIM-3 is operably linked to an endogenous regulatory element at the endogenous TIM-3 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIM-3 comprises a sequence encoding an amino acid sequence that is at least 70% identical to (SEQ ID NO: 26.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIM-3 comprises a sequence encoding an amino acid sequence that is at least 70% claim 1 , identical to SEQ ID NO: 30.5. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIM-3 comprises a sequence encoding an amino acid sequence that corresponds to amino acids 22-128 of SEQ ID NO: 26.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a C57BL/6 mouse.8. The animal of claim 1 , wherein the animal does not express endogenous TIM-3.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric TIM-3.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement claim 1 , at an endogenous TIM-3 gene locus claim 1 , of a sequence encoding a region of endogenous TIM-3 with a sequence encoding a corresponding region of human TIM-3.13. (canceled)14. (canceled)15. The animal of claim 12 , wherein the region of endogenous TIM-3 locus is the extracellular region of TIM-3.16. The animal of claim 12 , wherein the animal ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD94 AND/OR NKG2A

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD94 and/or NKG2A, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC PD-1

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric PD-1.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric PD-1 is operably linked to an endogenous regulatory element at the endogenous PD-1 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric PD-1 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 35.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric PD-1 comprises a sequence encoding an amino acid sequence that is at least 80% identical to SEQ ID NO: 33.5. The animal of claim 1 , wherein the sequence encoding a human or chimeric PD-1 is operably linked to a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element and/or a polyA (polyadenylation) signal sequence.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous PD-1.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric PD-1.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous PD-1 with a sequence encoding a human PD-1 or a chimeric PD-1 at an endogenous PD-1 gene locus.1314.-. (canceled)15. The animal of claim 12 , wherein the replaced locus is located after start codon at the endogenous PD-1 locus.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric PD-1 having an extracellular region claim 12 , a transmembrane ...

Genetically modified non-human animal with human or chimeric IL15

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.

Humanized transgenic animal

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47

This disclosure relates to genetically modified immunodeficient animals which express a human or chimeric (e.g., humanized) SIRPα and/or human or chimeric (e.g., humanized) CD47, and methods of use thereof.

Genetically Modified Non-Human Animal With Human Or Chimeric TIGIT

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric T cell immunoreceptor with Ig and ITIM domains (TIGIT).2. The animal of claim 1 , wherein the sequence encoding the human or chimeric TIGIT is operably linked to an endogenous regulatory element at the endogenous TIGIT gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIGIT comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 30.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIGIT comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 34.5. The animal of claim 1 , wherein the sequence encoding a human or chimeric TIGIT comprises a sequence encoding an amino acid sequence that corresponds to amino acids 24-127 of SEQ ID NO: 30.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous TIGIT.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric TIGIT.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement claim 1 , at an endogenous TIGIT gene locus claim 1 , of a sequence encoding a region of endogenous TIGIT with a sequence encoding a corresponding region of human TIGIT.13. (canceled)14. (canceled)15. The animal of claim 12 , wherein the region of endogenous TIGIT is the extracellular region of TIGIT.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric TIGIT having an extracellular region ...

Fast startup control circuit for switch mode power supply

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch.

Genetically Modified Non-Human Animal With Human Or Chimeric OX40

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Genetically modified mice expressing humanized CD40

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.

Base station antenna and base station

A base station antenna and a base station including the base station antenna are provided. A base station antenna includes a transceiver array configured to output M signals, wherein M is an integer greater than 1; an antenna array including N antenna units, wherein N is an integer greater than M; a first-level signal allocating network configured to allocate first power to the M signals, and output P signals, wherein P is an integer greater than M; a signal synthesizing network including multiple signal synthesizers, wherein each of the multiple signal synthesizers utilizes two signals of the P signals to synthesize two output signals; and a second-level signal allocating network configured to allocate second power to signals output by the multiple signal synthesizers, and output N signals to the N antenna units.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD40

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric CD40.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric CD40 is operably linked to an endogenous regulatory element at the endogenous CD40 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD40 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 23.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD40 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 27.5. The animal of claim 1 , wherein the human or chimeric CD40 comprises a sequence that is at least 90% identical to amino acids 20-192 of SEQ ID NO: 23.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous CD40.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric CD40.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous CD40 with a sequence encoding a corresponding region of human CD40 at an endogenous CD40 gene locus.1314.-. (canceled)15. The animal of claim 12 , wherein the replaced locus is the extracellular region of CD40.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric CD40 having an extracellular region claim 12 , a transmembrane region claim 12 , and a cytoplasmic region claim 12 , wherein the extracellular region comprises a sequence that is at least ...

GENETICALLY MODIFIED ANIMAL WITH CANINE OR CHIMERIC PD-1

The present disclosure relates to genetically modified animals that express a canine or chimeric (e.g., caninized) programmed cell death protein 1 (PD-1), and methods of use thereof.

Genetically modified non-human animal with human or chimeric OX40

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Zero standby switching power supply solution

A switching mode power supply (SMPS) includes a power transistor coupled to the primary winding of transformer and a resistor coupled between the input power source and a control terminal of the power transistor for triggering a primary current flow through the power transistor for providing startup power. A primary side control circuit is configured to regulate the output of the SMPS. A secondary side control circuit is coupled to the secondary winding and being configured to provide a first electrical signal to the secondary winding when an output voltage of the SMPS is less than a first reference voltage, whereupon an awakening signal is induced in the auxiliary winding and causes the primary side control circuit to provide a turn-on signal to the power transistor. The primary side control circuit is configured to enter a standby mode or a normal operating mode in response to the awakening signal.

HUMANIZED TRANSGENIC ANIMAL

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof. 1145.-. (canceled)146. A genetically-modified non-human animal whose genome comprises a sequence encoding a human IL-17A protein.147. The animal of claim 146 , wherein the sequence encoding the human IL-17A protein is operably linked to an endogenous 5′UTR at an endogenous IL-17A gene locus.148. The animal of claim 146 , wherein the human IL-17A protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 4.149. The animal of claim 146 , wherein the human IL-17A protein comprises SEQ ID NO: 4.150. The animal of claim 146 , wherein the human IL-17A protein consists of SEQ ID NO: 4.151. The animal of claim 146 , wherein the animal expresses the human IL-17A protein.152. The animal of claim 146 , wherein the animal is a rodent.153. The animal of claim 146 , wherein the animal is a mouse.154. The animal of claim 146 , whose genome comprises a replacement of a sequence encoding an endogenous IL-17A protein with a corresponding sequence encoding the human IL-17A protein.155. The animal of claim 146 , wherein the animal further comprises a sequence encoding a human IL-17RA protein or a humanized IL-17RA protein.156. The animal of claim 146 , wherein the animal further comprises a sequence encoding a human TNF-α protein.157. A method of determining in vivo effectiveness of an agent targeting human IL-17/IL-17R signaling pathway claim 146 , for treating an autoimmune disease claim 146 , comprising:{'claim-ref': {'@idref': 'CLM-00146', 'claim 146'}, 'a) constructing a disease model using the animal of ;'}b) administering the agent to the animal; andc) evaluating the in vivo effectiveness of the agent targeting human IL-17/IL-17R signaling pathway.158. The method of claim 157 , wherein ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD27

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD27, and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric CD27.2. The animal of claim 1 , wherein the sequence encoding the human or chimeric CD27 is operably linked to an endogenous regulatory element at the endogenous CD27 gene locus in the at least one chromosome.3. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD27 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 18.4. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD27 comprises a sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 24.5. The animal of claim 1 , wherein the sequence encoding a human or chimeric CD27 comprises a sequence encoding an amino acid sequence that corresponds to amino acids 1-183 of SEQ ID NO: 18.6. The animal of claim 1 , wherein the animal is a rodent.7. The animal of claim 1 , wherein the animal is a mouse.8. The animal of claim 1 , wherein the animal does not express endogenous CD27.9. The animal of claim 1 , wherein the animal has one or more cells expressing human or chimeric CD27.1011.-. (canceled)12. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal comprises a replacement of a sequence encoding a region of endogenous CD27 with a sequence encoding a corresponding region of human CD27 at an endogenous CD27 gene locus.13. (canceled)14. (canceled)15. The animal of claim 12 , wherein the endogenous CD27 locus is the extracellular region of CD27.16. The animal of claim 12 , wherein the animal has one or more cells expressing a chimeric CD27 having an extracellular region claim 12 , a transmembrane region claim 12 , and a cytoplasmic region claim 12 , wherein the ...

Genetically modified non-human animal with human or chimeric LAG3

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.

Fast startup control circuit for switch mode power supply

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch.

Genetically modified non-human animal with human or chimeric CD28

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.

Genetically Modified Non-Human Animal With Human Or Chimeric OX40

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1B AND/OR IL1A

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL1B and/or IL1A, and methods of use thereof.

Genetically modified non-human animal with human or chimeric PD-1

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.

Genetically modified mouse comprising a chimeric TIGIT

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Genetically modified non-human animal with human or chimeric TIM-3

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.

IMMUNODEFICIENT NON-HUMAN ANIMAL

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof. 1. A genetically-modified , non-human animal whose genome comprise a disruption in the animal's endogenous CD132 gene , wherein the disruption of the endogenous CD132 gene comprises deletion of exon 2 of the endogenous CD132 gene.23.-. (canceled)4. The animal of claim 1 , wherein the disruption of the endogenous CD132 gene further comprises deletion of one or more exons or part of exons selected from the group consisting of exon 3 claim 1 , exon 4 claim 1 , exon 5 claim 1 , exon 6 claim 1 , exon 7 claim 1 , and exon 8 of the endogenous CD132 gene.5. The animal of claim 1 , wherein the disruption of the endogenous CD132 gene comprises deletion of exons 1-8 of the endogenous CD132 gene.6. The animal of claim 1 , wherein the disruption of the endogenous CD132 gene further comprises deletion of one or more introns or part of introns selected from the group consisting of intron 1 claim 1 , intron 2 claim 1 , intron 3 claim 1 , intron 4 claim 1 , intron 5 claim 1 , intron 6 claim 1 , and intron 7 of the endogenous CD132 gene.7. The animal of claim 1 , wherein the disruption consists ofdeletion of more than 150 nucleotides in exon 1,deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, anddeletion of more than 250 nucleotides in exon 8.8. The animal of claim 1 , wherein the animal is homozygous with respect to the disruption of the endogenous CD132 gene.9. (canceled)10. (canceled)11. The animal of claim 1 , wherein the length of the remaining exon sequences at the endogenous CD132 gene locus is less than 30% of the total length of all exon sequences of the endogenous CD132 gene.12. (canceled)13. A genetically-modified claim 1 , non-human animal claim 1 , wherein the genome of the animal does not have exon ...

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL2RA

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL2RA, and methods of use thereof.

ZERO STANDBY SWITCHING POWER SUPPLY SOLUTION

A switching mode power supply (SMPS) includes a power transistor coupled to the primary winding of transformer and a resistor coupled between the input power source and a control terminal of the power transistor for triggering a primary current flow through the power transistor for providing startup power. A primary side control circuit is configured to regulate the output of the SMPS. A secondary side control circuit is coupled to the secondary winding and being configured to provide a first electrical signal to the secondary winding when an output voltage of the SMPS is less than a first reference voltage, whereupon an awakening signal is induced in the auxiliary winding and causes the primary side control circuit to provide a turn-on signal to the power transistor. The primary side control circuit is configured to enter a standby mode or a normal operating mode in response to the awakening signal. 1. A switching mode power supply (SMPS) , comprising: a primary winding for coupling to an input power source;', 'a secondary winding for providing an output of the SMPS; and', 'an auxiliary winding;, 'a transformer havinga power transistor coupled to the primary winding;a resistor coupled between the input power source and a control terminal of the power transistor for triggering a primary current flow through the power transistor for providing startup power;a primary side control circuit coupled to the auxiliary winding and the power transistor, the primary side control circuit being configured to regulate the output of the SMPS by controlling the power switch in response to a feedback voltage signal that is representative of the output of the SMPS; anda secondary side control circuit coupled to the secondary winding and being configured to provide a first electrical signal to the secondary winding when an output voltage of the SMPS is less than a first reference voltage, whereupon an awakening signal is induced in the auxiliary winding and causes the primary side ...

FAST STARTUP CONTROL CIRCUIT FOR SWITCH MODE POWER SUPPLY

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch. 1. A controller for a switch mode power supply (SMPS) , the controller comprising:a first terminal for coupling to a startup resistor and to a control terminal of a power switch which is coupled to a primary winding of the power supply;where the controller is configured:during a startup, to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller; andduring a normal operation, to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply.2. The controller of claim 1 , wherein:during startup, the controller is configured to provide a current path for the amplified startup current to flow from an output of the power switch to charge up a startup capacitor and to provide the startup power to the controller; andduring normal operation, the controller is configured to separate the power switch from the startup capacitor, and to provide the power switch control signal by amplifying a pulsed ...

FAST STARTUP CONTROL CIRCUIT FOR SWITCH MODE POWER SUPPLY

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch. 1. A controller for a switch mode power supply (SMPS) having a power switch coupled to a primary winding for regulating an output of the power supply , wherein the controller is configured to provide a current signal for driving an NPN power switch , and the controller is also configured to provide a voltage signal for driving an NMOS power switch.2. The controller of claim 1 , comprising:a pulse generation circuit for providing a pulsed control signal; an RC pump circuit including a resistor coupled to a capacitor at a common node, the resistor being coupled to a first bias voltage, the capacitor being configured to receive the pulsed control signal; anda drive transistor having a gate coupled to the common node, and a source of the drive transistor coupled to the NPN or NMOS power switch for providing the current signal or the voltage signal, respectively, for regulating an output of the power supply.3. The controller of claim 2 , further comprising:a current mirror coupled between the drive transistor and a voltage supply; anda switch transistor coupled between the drive transistor and a ground.4. ...

FAST STARTUP CONTROL CIRCUIT FOR SWITCH MODE POWER SUPPLY

A control circuit for a switch mode power supply (SMPS) includes a power switch for coupling to a primary winding of the power supply and a startup resistor coupled to an external input voltage and to a control terminal of the power switch. The control circuit also includes a controller. During startup, the controller is configured to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller. During normal operation, the controller is configured to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply. The controller is configured to provide a current signal for driving an NPN power switch and to provide a voltage signal for driving an NMOS power switch. 1. A controller for a switch mode power supply (SMPS) , the controller comprising:a first terminal for coupling to a startup resistor and to a control terminal of a power switch which is coupled to a primary winding of the power supply;where the controller is configured:during a startup, to cause the power switch to amplify a startup current from an external input voltage through the startup resistor and provide a startup power to the controller; andduring a normal operation, to provide a power switch control signal to turn on and off the power switch for controlling a current flow in the primary winding and regulating an output of the power supply.2. The controller of claim 1 , wherein:during startup, the controller is configured to provide a current path for the amplified startup current to flow from an output of the power switch to charge up a startup capacitor and to provide the startup power to the controller; andduring normal operation, the controller is configured to separate the power switch from the startup capacitor, and to provide the power switch control signal by amplifying a pulsed ...

Foxn1 knockout non-human animal

Provided is a genetically modified non-human animals that have a disruption at the endogenous Foxn1 gene, and methods of use thereof.

Genetically modified non-human animal with human or chimeric il1b and/or il1a

Provided are genetically-modified, non-human animal whose genome comprises a sequence encoding a human or chimeric interleukin 1 beta or interleukin 1 alpha, methods and use thereof.

Tunnel wall-adhering shuttle platform and tunnel monitoring apparatus

A tunnel wall-adhering shuttle platform (30) and a tunnel monitoring apparatus (100) are provided, the tunnel wall-adhering shuttle platform (30) is suited to shuttling in water in a tunnel (20) below a shield well (10), the tunnel wall-adhering shuttle platform (30) includes a control apparatus (303), a winch (304), a cable (302), and a carrying platform (301) capable of floating on water, the control apparatus (303) is electrically connected to the winch (304), the carrying platform (301) is electrically connected to the control apparatus (303) by means of the cable (302), one end of the cable (302) is connected to the carrying platform (301) and the other end of the cable (302) is wound onto the winch (304), and the control apparatus (303) controls the release and retraction of the cable (302) such that the carrying platform (301) can shuttle in a reciprocating motion along the inner wall of the tunnel (20) in a wall-adhering manner. By means of the control apparatus (303) controlling the release and retraction of the cable (302), the carrying platform (301) can shuttle in a reciprocating motion and maintain a stable attitude on the inner wall of the tunnel (20), and a monitoring mechanism (40) can be mounted on the carrying platform (301) in order to monitor the condition of foreign matter throughout the tunnel (20).

Genetically modified non-human animal with human or chimeric il15

Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.

Animals with genetically modified immunoglobulin heavy chain

Provided are genetically modified animals expressing modified immunoglobulin heavy chains, and methods of use thereof.

Underwater cleaning device for marine life on sealing surface of gate, and device combination and cleaning method

An underwater cleaning device (100) for marine life on the sealing surface of a gate, the device being used for cleaning marine life attached to the sealing surface of a gate of a building structure (200). The cleaning device comprises a main structure (1), a cleaning structure installed on the main structure (1) and a rigging structure (3) fixed to the main structure (1). The rigging structure (3) is used to connect to a lifting device so as to drive the cleaning structure to move to a corresponding position on the sealing surface of the gate. The cleaning structure is used for cleaning the marine life on the sealing surface of the gate when the cleaning structure moves to the corresponding position on the sealing surface of the gate. The rigging structure (3) is connected to the lifting device, so that when the cleaning device is moved to the corresponding position on the sealing surface of the gate by means of the lifting device, the cleaning structure can clean marine life. Not only are the problems of the efficiency of the cleaning manner of a diver being low and potential personal safety hazards avoided, but the problem of the movement stability of magnetic adsorption being poor is also obsolete.

Genetically modified non-human animal with human or chimeric genes

Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL10R and/or a human or chimeric (e.g., humanized) IL10, and methods of use thereof.

Base station antenna and base station

The present disclosure puts forward a base station antenna, i.e., a base station. A base station antenna includes: a transceiver array, configured to output M signals, in which M is an integer greater than 1; an antenna array with N antenna units, in which N is an integer greater than M; a first-level signal allocating network, configured to allocate power to the M signals, and output P signals, in which P is an integer greater than M; a signal synthesizing network with multiple signal synthesizers, in which each signal synthesizer utilizes two signals of the P signals to synthesize two output signals, and enable the two output signals to meet respective corresponding predetermined phrase and predetermined amplitude; and a second-level signal allocating network, configured to allocate power to multiple signals outputted by the multiple signal synthesizers, and output N signals to the N antenna units.

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα

Provided herein are genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRPα, and methods of use thereof.

Genetically modified non-human animal with human or chimeric il17a and/or il17f

Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL17A and/or IL17F, and methods of use thereof.

Tunnel wall-adhering shuttle platform and tunnel monitoring apparatus

Genetically modified non-human animal with human or chimeric genes

Pontoon type tunnel shuttle platform, monitoring device and foreign matter monitoring method

Genetically modified non-human animal with human or chimeric ccr8

Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) CCR8, and methods of use thereof.

Signal processing apparatus, remote radio apparatus, and base station

The present disclosure discloses a signal processing apparatus, a remote radio apparatus, and a base station. The signal processing apparatus includes cascaded first crest factor reduction module (CFR1) and first pre-distortion module (PD1), in which the first crest factor reduction module (CFR1) outputs a first crest factor reduction signal (y1) to the first pre-distortion module (PD1), and the first pre-distortion module (PD1) outputs a first pre-distortion signal (x1); and a second pre-distortion module (PD2) with an output end coupled to an input end of the first crest factor reduction module (CFR1), to output a second pre-distortion signal (x2) to the first crest factor reduction module (CFR1).

Genetically modified non-human animal with human or chimeric mhc protein complex

宽电压抗干扰磁致伸缩液位传感器

本实用新型提供了一种宽电压抗干扰磁致伸缩液位传感器，包括脉冲隔离电路、检测电路和控制电路，脉冲隔离电路中，电容C2的一端连接控制电路以接收脉冲信号，三极管Q3和三极管Q4及其外围电路构成两级隔离电路，对干扰电压进行隔离，电容C2的另一端通过两级隔离电路控制连接双场管U5，进而控制电阻RL上的磁场变化；检测电路的输入端采样连接电阻RL，检测电路的输出端连接控制电路。该宽电压抗干扰磁致伸缩液位传感器具有抗干扰能力强、宽电压输入的优点。

Method and apparatus for signal processing

The application provides a signal processing system, a signal processing method and an electronic apparatus, which can improve the identification precision of a non-linear system. A signal processing system comprises: a fractional time delay generation unit, used for performing time delay processing on an input signal of the signal processing system to generate a fractional time delay signal; an integer time delay unit, used for performing time delay processing on the fractional time delay signal to generate an integer time delay processed signal; and a model processing unit, used for processing the integer time delay processed signal according to a mathematical model of the signal processing system to obtain an output signal of the signal processing system.

一种碗架

本实用新型公开了一种碗架，包括架体和隔板，所述的架体上设置有若干个隔板的固定槽，所述的隔板安装在固定槽内，通过隔板安装固定槽位置变换可实现相邻隔板之间间距的调节，相邻隔板之间形成放置餐具的置物槽；本实用新型置物槽的大小可以根据盘或碗的大小调节，使用灵活方便；另外，还在柜子上设置了通风的结构，能让碗架内部通风。

Cosmetic emulsion with diisopropyl adipate and polyglycerylester

The present invention belongs to the cosmetic field, and relates to cosmetic oil in water emulsion comprising a combination of diisopropyl adipate and at least one polyglycerylester. This combination allows for a thickening of oil in water emulsions, and the emulsion has a low tackiness.

Cosmetic emulsion with diisopropyl adipate and polyglycerylester

Cosmetic oil in water emulsion comprises the combination of diisopropyl adipate and at least one polyglycerylester. The emulsion is thickened by the combination and has a low tackiness.

Pontoon type tunnel shuttle platform, monitoring device and foreign matter monitoring method